# Galatea Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/galatea-bio

- Industry: Biotechnology
- Headquarters: Miami Lakes, US
- Website: www.galatea.bio/
- Total disclosed funding: $25M
- Latest round: Series A (Mar 27, 2025)
- Investors on record: 8

## About

Galatea Bio, Inc. specializes in clinical testing and biobanking services that leverage human genetic diversity to enhance biomedicine, aiming to address genetic health disparities and improve patient care through innovative genomic solutions.Founded in 2020, Galatea Bio, Inc. operates in Miami Lakes, US, focusing on providing genomic services. The company has engaged in two total deals, with its most recent funding round occurring in March 2025. The founder’s history includes previous entrepreneurial ventures, although specific details are not provided. The firm has not been noted as a subsidiary or involved in significant pivots since its founding.Galatea Bio's primary offerings center around clinical testing and biobanking services that harness human genetic diversity to address pressing challenges in biomedicine. Their core products include next-generation sequencing molecular diagnostics and a comprehensive biobank, which are both CLIA-CMS certified and CAP-accredited, ensuring high-quality results for clients. The company provides a testing catalog that enables physicians to investigate genetic variations and biological pathways that are critical for patient care. Galatea Bio collaborates with pharmaceutical companies, academic institutions, and health systems globally, focusing on large-scale population sequencing programs. Geographically, their services are utilized across North America and Latin America, with specific initiatives aimed at addressing genetic health disparities among diverse populations.Galatea Bio generates revenue primarily through partnerships and collaborations with pharmaceutical and life sciences organizations, as well as through academic institutions that utilize their biobanking and sequencing services. Business transactions typically occur through contractual agreements where clients engage Galatea Bio to conduct genetic testing and analysis, enabling them to access a wealth of genomic data for research and development purposes. The company’s flagship offering, StrataRisk™, provides polygenic risk scores for common diseases, which further supports its revenue model by catering to healthcare providers interested in precision medicine. By establishing long-term partnerships that often involve subscription-based access to their data resources and testing services, Galatea Bio solidifies its role as a vital contributor to advancing genomic research and healthcare innovation.In March 2025, Galatea Bio, Inc. raised USD 25 mn in venture funding with participation from new investors including Alexandria Corp., AME Cloud Ventures, CEI Ventures Management, Digitalis Ventures, Founder Collective, F-Prime Capital, HBM Genomics, and Helios Investment Partners. The funding will be utilized to expand their biobank, enhance genomic analysis, and support biomarker discovery initiatives. The company is also planning to introduce new products aimed at improving healthcare outcomes and is targeting expansion into additional markets in Latin America by 2026.

## Funding rounds

- Series A, Mar 27, 2025, $25M — CEI Ventures Management, F-Prime Capital, Helios Investment Partners, Founder Collective, AME Cloud Ventures, Digitalis Ventures, HBM Genomics, Alexandria Corp.

## Investors

- CEI Ventures Management (https://capitalatlas.ai/funds/cei-ventures-management) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Helios Investment Partners (https://capitalatlas.ai/funds/helios-investment-partners) — Series A
- Founder Collective (https://capitalatlas.ai/funds/founder-collective) — Series A
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A
- HBM Genomics (https://capitalatlas.ai/funds/hbm-genomics) — Series A
- Alexandria Corp. — Series A